Skip to content

A clinical study to evaluate the safety and efficacy of Nimson Kesh silk Plus oil in controlling hairfall and premature greying

A Prospetive, single arm, open label, single centre clinical study to evaluate the safety and efficacy of Nimson kesh silk plus oil in controlling hairfall and premature greying - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/06/054313
Enrollment
30
Registered
2023-06-22
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

None listed

Sponsors

Aryanveda Cosmeceuticals
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Subjects aged between 18 to 65 years. Patients having Khalitya (Baldness) and Palitya (premature Greying) as per Ayurvedic classical texts and as per modern parameters i.e., Hair fall, Dandruff and Dryness of hairs have been selected irrespective of any bar of caste, gender, religion and occupation.

Exclusion criteria

Exclusion criteria: Signs of allergy, irritation or intolerance to the components of the test product Patients who have been diagnosed to have local disease like Alopecia areata, Alopecia totalis, Tinea capitis, Folliculitis devaculans. Patient with hair fall related to any Systemic disorders, any Hormonal disorders, Post CA treatments and Vitiligo. Pregnancy or lactation. Participation in other clinical trials. Unwilling/unable to sign the informed consent.

Design outcomes

Primary

MeasureTime frame
• Reduced hairfall as per the 60 seconds hairfall on Day 28 when compared with the baseline value • Improvement in the Greying Severity score in comparison with the baselineTimepoint: day 28

Secondary

MeasureTime frame
• Increase in hair length to establish the ability of the oil to Nourish the hair. • Number of subjects experiencing eye or skin irritation or any adverse events in the treatment phase.Timepoint: day 42

Countries

India

Contacts

Public ContactSunita C

Aryanveda Cosmoceuticals

vijaykimtata.vk@gmail.com9816333352

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026